News

Ideas That Generate Results

The patents of some of the major rapid acting insulin analogs are set to expire in 2014. This surge of patent expiries is set to create opportunities for biosimilar players such as Biocon and Wockhardt. In fact, global players such as Sanofi are also banking on the launch of next generation insulin to counteract the loss from patent expiration from biologic molecules. The pipeline for insulin biosimilars is dominated by Biocon and Wockhardt. Wockhardt’s Lispro is in Phase III whereas Biocon’s products are in preclinical phase. The largely untapped market of insulin biosimilars provides opportunistic areas for manufacturers who have potential and resources to cater to the rising demand.
 
Increasing prevalence of diabetes patient population will boost the growth of insulin market which may reach to approximately US$ 45 Billion by the end of 2018. According to RNCOS Research Report, “Global Insulin Market Outlook 2018”, the growth is also attributed because of the innovation in insulin delivery devices.
 
The report takes into account the key aspects of the global insulin market and projects the market during 2013-2018. Our report prudently analyzed major players, their product portfolio, recent developments, diabetes prevalence across different geographies, current and future market size for global insulin market as well as geographical markets of India, China, US, Russia, etc. Our comprehensive research work also studies how patent expiry of block buster insulin products would create opportunities for biosimilars.
 
Overall, the report aims at providing reliable and complete information about the global insulin market to clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM681.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm